成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ChemicalBook >> journal list >> Biomedicine & Pharmacotherapy >>article
Biomedicine & Pharmacotherapy

Biomedicine & Pharmacotherapy

IF: 6.9
Download PDF

Therapeutic effects of guanidine hydrochloride on breast cancer through targeting KCNG1 gene.

Published:1 August 2023 DOI: 10.1016/j.biopha.2023.114982 PMID: 37311278
Mehdi Roshanian Bakhsh, Leila Rouhi, Kamran Ghaedi, Mehrdad Hashemi, Maryam Peymani, Saeed Samarghandian

Abstract

Background: Triple-negative breast cancer (TNBC) is one of the subtypes of breast cancer (BC) that is associated with poor survival rates and failure to respond to hormonal and targeted therapies.

Objective: The aim of this study was to identify a specific gene at the expression level for TNBC and targeting of this type of breast cancer based on it. Using TCGA database, genes that are particularly high expression in TNBC subtypes compared to other BC subtypes (in terms of receptor status) and normal samples were identified and their sensitivity and specificity were evaluated. Using PharmacoGX and Drug Bank data, drug sensitivity and drug-appropriate genes were identified, respectively. The effects of the identified drug on triple-negative cell lines (MDA-MB-468) were evaluated in comparison with the cell line of other subtypes (MCF7) by apoptosis and MTS tests.

Results: Data analyzes showed that the expression level of KCNG1 gene in the TNBC subgroup was significantly higher compared to other BC subtypes from the KCN gene family and ROC results showed that this gene had highest sensitivity and specificity in TNBC subtype. The results of drug resistance and sensitivity showed that an increase in the expression level of KCNG1 was associated with sensitivity to Cisplatin and Oxaliplatin. Moreover, Drug Bank results showed that Guanidine hydrochloride (GuHCl) was a suitable inhibitor for KCNG1. In vitro results showed that the expression level of KCNG1 was higher in MDA-MB-468 compared to MCF7. In addition, the rate of apoptosis in response to GuHCl treatment in MDA-MB-468 cell line as TNBC cell model was higher than MCF7 in the same concentration.

Conclusion: This study revealed that GuHCl could be a suitable treatment for TNBC subtype by targeting of KCNG1.

Substances (3)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Guanidine hydrochloride 50-01-1 CH5N3.ClH 854 suppliers $5.00-$13385.00
Cisplatin 15663-27-1 Cl2H6N2Pt 769 suppliers $17.00-$6890.00
Oxaliplatin 63121-00-6 C8H12N2O4Pt 170 suppliers Inquiry

Similar articles

IF:4.6

Targeting cuproptosis by zinc pyrithione in triple-negative breast cancer.

iScience Xu Yang,?Li Deng,etc Published: 16 October 2023
IF:4.3

Cadaverine, a metabolite of the microbiome, reduces breast cancer aggressiveness through trace amino acid receptors.

ACS Applied Electronic Materials Tünde Kovács, Edit Mikó,etc Published: 4 February 2019
IF:4.3

Evaluation of the antiseptic and wound healing potential of polyhexamethylene guanidine hydrochloride as well as its toxic effects

European Journal of Pharmaceutical Sciences Fernanda Gosuen Gon?alves Dias , Lucas de Freitas Pereira ,etc Published: 1 May 2021